BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anacetrapib: Phase III data

The double-blind, international Phase III DEFINE trial in 1,623 patients with CHD or CHD risk-equivalent disease who were already receiving statins and were at a guideline-established LDL-C goal showed that once-daily 100 mg anacetrapib for 76 weeks met the primary endpoint of significantly reducing LDL-C from baseline to week 24 vs. placebo (36 vs. 5 mg/dL, p<0.001). Specifically, anacetrapib reduced LDL-C from 81 mg/dL at baseline to 45 mg/dL at...

Read the full 330 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >